<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="62151">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01996436</url>
  </required_header>
  <id_info>
    <org_study_id>IVT_201310 (HSC-MS-13-0586)</org_study_id>
    <nct_id>NCT01996436</nct_id>
  </id_info>
  <brief_title>The Intra-arterial Vasospasm Trial</brief_title>
  <acronym>IVT</acronym>
  <official_title>The Intra-arterial Vasospasm Trial- A Multi-center Randomized Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University at Buffalo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Thomas Jefferson University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Illinois at Chicago</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Texas Health Science Center, Houston</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to determine the optimal intra-arterial drug therapy
      and most effective treatment regiment for treating cerebral vasospasm following aneurysmal
      subarachnoid hemorrhage. We hypothesize that combination of multiple drug agents infusion
      (nicardipine +verapamil + nitroglycerin) will likely improve the treatment efficacy compared
      to single agents (nicardipine or milrinone or verapamil).

      All procedures done as a part of this study are standard hospital care procedures done to
      treat cerebral vasospasm and all drugs to be used are FDA approved.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of the study is to determine the optimal intra-arterial drug treatment
      therapy regiment for treating cerebral vasospasm following aneurysmal subarachnoid
      hemorrhage.

      The secondary objective is to evaluate the functional clinical outcome post optimal
      intra-arterial drug therapy for cerebral vasospasm following aneurysmal subarachnoid
      hemorrhage.

      This study is a multicenter randomized trial. The outcome variable to evaluate primary
      objective is to measure the pre &amp; post intra-arterial infusion blood vessel diameter in the
      presenting vasospasmic blood vessel to measure the Post infusion improvement ratio (PIIR).
      Modified Rankin score (mRs) at 3 months post hospital discharge will be recorded to study
      the secondary objective for functional clinical outcome.

      The interventions in this study trial are a part of standard hospital routine care
      procedures for vasospasm treatment. Following surgical or endovascular intervention for
      aneurysm rupture if patients develop cerebral vasospasm refractory to medical management
      then endovascular treatment (intra-arterial FDA approved single agents or cocktail agents
      drug infusion) will be initiated.

      Study participants will be randomly assigned to one of the four treatment groups where one
      single agent drug or cocktail agents will be intra-arterially administered. Pre &amp; post
      infusion vasospasmic vessel diameters will be compared. The change in diameter will be
      quantified based on the mean percentage. Six weeks post hospital discharge study
      participants will be followed up at clinic to evaluate functional outcome. The total
      duration for study participation required is the standard hospital stay for post aneurysm
      vasospasm treatment and one follow-up clinic visit at 3months.

      The study will require 224 patients in total for 89% power to detect difference. Hence 28
      subjects in total at each of the 8 participating centers will be enrolled. The patient
      population will be hospitalized patients presenting with cerebral vasospasm post aneurysmal
      subarachnoid hemorrhage.

      Subjects will be stratified by randomization into 4 treatment groups.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">April 2015</completion_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Health Services Research</study_design>
  <primary_outcome>
    <measure>Post infusion improvement ratio(PIIR)</measure>
    <time_frame>pre pharmacological angioplasty blood vessel diameter - 0 min, post pharmacological angioplasty blood vessel diameter- 10 min after infusion</time_frame>
    <safety_issue>No</safety_issue>
    <description>Post infusion improvement ratio(PIIR) = (B - A) / A
A = pre-infusion blood vessel diameter B = post infusion blood vessel diameter
PIIR across all four treatment arms will be compared and tested for statistical significance.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To grade clinical outcome using Modified Rankin score</measure>
    <time_frame>6 weeks post discharge from hospital</time_frame>
    <safety_issue>No</safety_issue>
    <description>Clinical outcome at 6 weeks post discharge from hospital after treatment will be evaluated using Modified Rankin score</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Intra-cranial pressure</measure>
    <time_frame>1 day prior to procedure &amp; 1 day after the procedure</time_frame>
    <safety_issue>No</safety_issue>
    <description>Intra-cranial pressure will be measured 1 day prior to vasospasm treatment and 1 day after vasospasm treatment</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">224</enrollment>
  <condition>Cerebral Vasospasm</condition>
  <arm_group>
    <arm_group_label>Nicardipine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group 1 : Nicardipine 5mg per circulation intra-arterial injection, Pharmacological angioplasty</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Milrinone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group 2 : Milrinone, 5mg per circulation, intra-arterial injection, Pharmacological angioplasty</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Verapamil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group 3: Verapamil 10mg per circulation intra-arterial injection, Pharmacological angioplasty</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nicardipine + Verapamil + Nitroglycerin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group 4 : Nicardipine 5mg + Verapamil 10mg + Nitroglycerin 200mcg in 4cc 5 % dextrose in water , intra-arterial injection, Pharmacological angioplasty</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicardipine</intervention_name>
    <description>Pharmacological angioplasty: intra-arterial drug infusion via catheter to treat cerebral vasospasm</description>
    <arm_group_label>Nicardipine</arm_group_label>
    <other_name>Cardene</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Milrinone</intervention_name>
    <description>Pharmacological angioplasty: intra-arterial drug infusion via catheter to treat cerebral vasospasm</description>
    <arm_group_label>Milrinone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Verapamil</intervention_name>
    <description>Pharmacological angioplasty: intra-arterial drug infusion via catheter to treat cerebral vasospasm</description>
    <arm_group_label>Verapamil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicardipine + Verapamil + Nitroglycerin</intervention_name>
    <description>Pharmacological angioplasty: intra-arterial drug infusion via catheter to treat cerebral vasospasm</description>
    <arm_group_label>Nicardipine + Verapamil + Nitroglycerin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patient, age 18-80 years old, with ruptured aneurysm(s) who experience cerebral
             vasospasm post operatively within 3-21 days.

        Exclusion Criteria:

          -  Inability to obtain consent from patient or patients kin

          -  Pregnant women

          -  less than 18 years of age of more than 80 years of age
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peng R Chen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas Medical School at Houston</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ketan R Bulsara, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Peng R Chen, MD</last_name>
    <phone>713-704-7100</phone>
    <email>Peng.R.Chen@uth.tmc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Aditya A Sanzgiri, MBBS, MPH</last_name>
    <phone>713-704-7100</phone>
    <phone_ext>7263</phone_ext>
    <email>Aditya.A.Sanzgiri@uth.tmc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Yale School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ketan R Bulsara, MD</last_name>
      <phone>203-737-2096</phone>
      <email>ketan.bulsara@yale.edu</email>
    </contact>
    <investigator>
      <last_name>Ketan R Bulsara, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Illinois College of Medicine at Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ali Alaraj, MD</last_name>
      <phone>312-996-4842</phone>
      <email>alaraj@uic.edu</email>
    </contact>
    <investigator>
      <last_name>Ali Alaraj, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guiseppe Lanzino, MD</last_name>
      <phone>507-284-2511</phone>
      <email>Lanzino.Guiseppe@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Guiseppe Lanzino, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine in St. Louis</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Colin P Derdeyn, MD</last_name>
      <phone>314-362-5580</phone>
      <email>derdeync@mir.wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Colin P Derdeyn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Buffalo</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adnan H Siddiqui, MD</last_name>
      <phone>716-218-1000</phone>
      <email>adnan.h.siddiqui@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Adnan H Siddiqui, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pascal M Jabbour, MD</last_name>
      <phone>215-955-7000</phone>
      <email>Pascal.Jabbour@jefferson.edu</email>
    </contact>
    <investigator>
      <last_name>Pascal M Jabbour, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew F Durcruet, MD</last_name>
      <phone>412-864-1839</phone>
      <email>ducruetaf@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Andrew F Ducruet, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Medical School at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peng R Chen, MD</last_name>
      <phone>713-704-7100</phone>
      <email>peng.r.chen@uth.tmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Aditya A Sanzgiri, MBBS MPH</last_name>
      <phone>713-704-7263</phone>
      <email>Aditya.A.Sanzgiri@uth.tmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Peng R Chen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Dorsch NW, King MT. A review of cerebral vasospasm in aneurysmal subarachnoid haemorrhage Part I: Incidence and effects. J Clin Neurosci. 1994 Jan;1(1):19-26.</citation>
    <PMID>18638721</PMID>
  </reference>
  <reference>
    <citation>Treggiari MM, Walder B, Suter PM, Romand JA. Systematic review of the prevention of delayed ischemic neurological deficits with hypertension, hypervolemia, and hemodilution therapy following subarachnoid hemorrhage. J Neurosurg. 2003 May;98(5):978-84. Review. Erratum in: J Neurosurg. 2003 Dec;99(6):1119.</citation>
    <PMID>12744357</PMID>
  </reference>
  <reference>
    <citation>Biller J, Godersky JC, Adams HP Jr. Management of aneurysmal subarachnoid hemorrhage. Stroke. 1988 Oct;19(10):1300-5.</citation>
    <PMID>3176090</PMID>
  </reference>
  <reference>
    <citation>Kassell NF, Sasaki T, Colohan AR, Nazar G. Cerebral vasospasm following aneurysmal subarachnoid hemorrhage. Stroke. 1985 Jul-Aug;16(4):562-72. Review.</citation>
    <PMID>3895589</PMID>
  </reference>
  <reference>
    <citation>Keuskamp J, Murali R, Chao KH. High-dose intraarterial verapamil in the treatment of cerebral vasospasm after aneurysmal subarachnoid hemorrhage. J Neurosurg. 2008 Mar;108(3):458-63. doi: 10.3171/JNS/2008/108/3/0458.</citation>
    <PMID>18312091</PMID>
  </reference>
  <reference>
    <citation>Linfante I, Delgado-Mederos R, Andreone V, Gounis M, Hendricks L, Wakhloo AK. Angiographic and hemodynamic effect of high concentration of intra-arterial nicardipine in cerebral vasospasm. Neurosurgery. 2008 Dec;63(6):1080-6; discussion 1086-7. doi: 10.1227/01.NEU.0000327698.66596.35.</citation>
    <PMID>19057319</PMID>
  </reference>
  <reference>
    <citation>Badjatia N, Topcuoglu MA, Pryor JC, Rabinov JD, Ogilvy CS, Carter BS, Rordorf GA. Preliminary experience with intra-arterial nicardipine as a treatment for cerebral vasospasm. AJNR Am J Neuroradiol. 2004 May;25(5):819-26.</citation>
    <PMID>15140728</PMID>
  </reference>
  <reference>
    <citation>Pierot L, Aggour M, Moret J. Vasospasm after aneurysmal subarachnoid hemorrhage: recent advances in endovascular management. Curr Opin Crit Care. 2010 Apr;16(2):110-6. doi: 10.1097/MCC.0b013e3283372ef2. Review.</citation>
    <PMID>20098322</PMID>
  </reference>
  <reference>
    <citation>Fraticelli AT, Cholley BP, Losser MR, Saint Maurice JP, Payen D. Milrinone for the treatment of cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Stroke. 2008 Mar;39(3):893-8. doi: 10.1161/STROKEAHA.107.492447. Epub 2008 Jan 31.</citation>
    <PMID>18239182</PMID>
  </reference>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 9, 2014</lastchanged_date>
  <firstreceived_date>November 12, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center, Houston</investigator_affiliation>
    <investigator_full_name>Peng Roc Chen</investigator_full_name>
    <investigator_title>Assistant Professor - Neurosurgery</investigator_title>
  </responsible_party>
  <keyword>cerebral vasospasm</keyword>
  <keyword>aneurysmal subarachnoid hemorrhage</keyword>
  <keyword>intra arterial drug treatment for cerebral vasospasm</keyword>
  <keyword>nicardipine milrinone nitroglycerin verapamil</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vasospasm, Intracranial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Verapamil</mesh_term>
    <mesh_term>Nitroglycerin</mesh_term>
    <mesh_term>Nicardipine</mesh_term>
    <mesh_term>Milrinone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
